Biotherapy and Cellular Therapy

See the publications

The Marseille Cancer Research Center celebrates its 50th anniversary ! -


The Centre d’Investigation Clinique en Biothérapies (CBT-510) was created in 2005 by Inserm, Aix-Marseille University, IPC and AP-HM, following a call jointly published by Inserm, the DHOS division at the French Ministry of Health and several other partners interested in the development and validation of innovative biological therapies.

The project places a strong emphasis on sharing experience in cell and tissue engineering, clinical-grade and scale technique validations, development of biological assays used to evaluate the potency of cell therapy products and products of tissue engineering, or to evaluate efficiency and safety in patients (surrogate markers), and knowledge and compliance with fast evolving regulatory aspects.

The CBT-510 associates the cell therapy facility (“Centre de Thérapie Cellulaire et Génique”, CTCG;) at IPC for oncology, with the cell and tissue engineering facility (“Laboratoire de Culture et de Thérapie Cellulaire”, LCTC) at Hôpital de la Conception for other medical fields.

The CBT 510 was evaluated by AERES in 2010, and funded again following this evaluation..

The procedure to request access to biological samples is indicated on the Biobank page.

The cell therapy facility

The Cell Therapy Facility (“Centre de Thérapie Cellulaire et Génique”, CTCG) is an infrastructure dedicated to collection, engineering, cryopreservation and distribution of biological samples for therapeutic use. It supports the autologous and allogeneic hematopoietic stem cell transplantation (bone marrow transplantation) programs at IPC and at AP-HM.
It is one of the largest such structures hosted in a hospital in Europe, and hosts the Marseille cord blood bank for which IPC and AP-HM partners with the Établissement Français du Sang Alpes-Méditerranée (EFS-AM, Blood Bank).

The CTCG is both a service provider and a R&D centre for state of the art methods in human cell engineering, and is a founding member of the "Centre d’Investigations Cliniques en Biothérapie de Marseille", INSERM CBT-510.

The CTCG has established a partnership with biotech companies for the development of several information systems and reagents useful for biobanking and bio-engineering, (Modul-Bio Inc., Miltenyi Biotec, Sepax …), as well as with biotechnology companies that develop innovative tools targeting components of the hematopoietic system (Innate Pharma).